jakavi
novartis europharm limited - ruxolitiniib (fosfaadina) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastilised ained - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi on näidustatud ravi täiskasvanud patsientidel, kellel polycythaemia vera, kes on resistentsed või sallimatu hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.
lorviqua
pfizer europe ma eeig - lorlatinib - kartsinoom, mitteväikerakk-kopsu - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
femoston conti 0,5 mg/2,5 mg õhukese polümeerikattega tablett
viatris healthcare limited - düdrogesteroon+östradiool - õhukese polümeerikattega tablett - 2,5mg+0,5mg 280tk; 2,5mg+0,5mg 28tk
destele tablett
teva pharma b.v. - desogestreel+etünüülöstradiool - tablett - 150mcg+30mcg 273tk; 150mcg+30mcg 126tk; 150mcg+30mcg 63tk; 150mcg+30mcg 21tk
femoston conti õhukese polümeerikattega tablett
viatris sia - düdrogesteroon+östradiool - õhukese polümeerikattega tablett - 5mg+1mg 28tk
destele tablett
teva pharma b.v. - desogestreel+etünüülöstradiool - tablett - 150mcg+20mcg 63tk; 150mcg+20mcg 126tk
regulon õhukese polümeerikattega tablett
gedeon richter plc. - desogestreel+etünüülöstradiool - õhukese polümeerikattega tablett - 0,15mg+0,03mg 21tk
femoston õhukese polümeerikattega tablett
viatris sia - düdrogesteroon+östradiool - õhukese polümeerikattega tablett - 0+1mg/10mg+1mg 14tk / 14tk
gracial tablett
aspen pharma trading limited - desogestreel+etünüülöstradiool - tablett - 25mcg+40mcg/125mcg+30mcg 21tk / 45tk; 25mcg+40mcg/125mcg+30mcg 7tk / 15tk
novynette õhukese polümeerikattega tablett
lex ano uab - desogestreel+etünüülöstradiool - õhukese polümeerikattega tablett - 0,15mg+0,02mg 21tk; 0,15mg+0,02mg 63tk